Joint venture between Ultra Health, Panaxia brings smokeless cannabis medicine to United States
(Albuquerque, New Mexico) – Ultra Health®, New Mexico’s No. 1 cannabis company with a nationwide presence, and Panaxia Pharmaceuticals Industries Ltd, an Israeli pharmaceutical company specializing in pharmaceutical cannabis R&D and manufacturing, launched the first pharmaceutical cannabis production facility in the United States, located in Bernalillo, New Mexico. The facility will manufacture smokeless, accurately dosed cannabis medicine in a variety of delivery methods.
Panaxia is providing smokeless proprietary cannabinoid dosage and treatment protocols, which are not readily available in the United States, in order to manufacture state-of-the-art products to treat a number of illnesses. The production facility is implementing Panaxia's technology, including advanced Good Manufacturing Practice (GMP) production protocols as well as validated analytical system and proprietary production technology.
The smokeless products include sublingual and oral tablets, rectal and vaginal suppositories, cannabis oil, pastilles, transdermal pain relief patches and topical creams for the treatment of pain, burns and psoriasis. They are beneficial to current chronic conditions requiring ongoing dosing such as PTSD, chronic pain, cancers, neuropathy pain, epilepsy, anorexia and HIV/AIDS. The products will be available at the end of March.
“The new 18 smokeless-designed cannabis products are providing better delivery systems for patients and physicians by delivery of a fully potent, targeted dosage specifically tailored to the patient’s needs,” said Duke Rodriguez, CEO and President of Ultra Health. “Patients will also have the opportunity to purchase products containing only Tetrahydrocannabinol (THC), products containing only Cannabidiol, (CBD) as well as products with an equal THC and Cannabidiol (CBD) ratio.”
"At Ultra Health, our mission is to provide superior-quality and affordable medical grade cannabis to New Mexico patients,” Rodriguez said. “Ultra Health is driven by compassionate innovation and supported by science and technology. It is important that we develop new products in anticipation of meeting the rapidly growing patient and provider demands.”
"We are extremely excited to open our first production facility in the United States,” said Dr. Dadi Segal, CEO of Panaxia. “It is history in the making for an Israeli company to bring the tidings to the citizens of New Mexico. Panaxia is part of an organization that has been active in the Israeli and global pharmaceutical industry for more than 40 years. Since we established Panaxia in 2010, we constantly strive to bring the strictest protocols and most advanced technology available in the pharma industry to the production of our cannabis based products. At Panaxia, we believe that pharmaceutical cannabis products should be developed and manufactured under the highest standards and quality assurance levels like any other pharmaceutical product. We are happy to move forward into bringing smokeless, exact and reproducible dosing capabilities for medical cannabis products to the United States market. We believe in the coming months of 2017 both companies will be launching additional production facilities.”
About Ultra Health
Ultra Health is a turnkey solutions provider for the specialty healthcare cannabis industry, with operations and facilities in Arizona, New Mexico, and Nevada. From retail dispensaries to commercial-scale cannabis production, Ultra Health offers the unmatched technical expertise, proprietary business tools and deep industry knowledge to fulfill the specific requirements of any project related to the cannabis industry. Ultra Health partners with a broad spectrum of businesses and Tribal Nations to design, formulate and manage cannabis-related economic development opportunities that are profitable, scalable and mutually beneficial.
About Panaxia Pharmaceutical Industries Ltd
Panaxia Pharmaceutical Industries is a manufacturer of pharmaceutical dosage forms based on Cannabis. The company is part of a larger group of companies, which have manufactured pharmaceuticals for more than 40 years. Altogether, the group produces more than 300 different conventional medication products, with a wide range of indications from sore throat lozenges to dermal fillers. The group sells in more than 25 countries and is very R&D oriented. Panaxia Pharmaceutical Industries has been developing and manufacturing pharmaceutical products based on cannabis since 2010.